BECTON DICKINSON & CO
Becton, Dickinson and Company (BDX) is a global medical technology firm supplying devices, instruments and reagents used by hospitals, laboratories and life‑science researchers. Its portfolio includes needles and syringes, medication‑management systems, diagnostic instruments and biosciences tools, producing a high share of recurring revenue and relatively predictable cash flows. With a market capitalisation of around $54.18 billion, BDX benefits from steady demand driven by hospital procedures, chronic disease management and diagnostic testing. Investors tend to focus on margin trends, capital allocation (dividends and buybacks), R&D and acquisition activity. Key risks include regulatory scrutiny, litigation, reimbursement pressure and sensitivity to hospital capital spending and global economic conditions. Longer‑term growth is supported by demographic trends and ongoing innovation in diagnostics, though past performance is not a reliable indicator of future returns. This is general educational information only and not personalised investment advice; suitability depends on your individual circumstances.
Why It's Moving
BDX Stock Forecast 2026: Why Analysts Target +17% Upside
- Wall Street's median price target of around $190 implies over 17% upside from recent levels, driven by strong demand for innovative medical solutions.
- No sell ratings among major firms, with six buys and nine holds reflecting confidence in BDX's market cap stability and 2.51% dividend yield.
- Technical indicators like a rising 50-day moving average and neutral RSI signal balanced momentum, bolstering the case for upward trajectory in medtech.
BDX Stock Forecast 2026: Why Analysts Target +17% Upside
- Wall Street's median price target of around $190 implies over 17% upside from recent levels, driven by strong demand for innovative medical solutions.
- No sell ratings among major firms, with six buys and nine holds reflecting confidence in BDX's market cap stability and 2.51% dividend yield.
- Technical indicators like a rising 50-day moving average and neutral RSI signal balanced momentum, bolstering the case for upward trajectory in medtech.
When is the next earnings date for BECTON DICKINSON & CO (BDX)?
BD (NYSE: BDX) is scheduled to report its next earnings for the second quarter of fiscal 2026 on May 7, 2026, before market open. This release covers the quarter ended March 31, 2026, with management hosting an audio webcast at 8:00 a.m. ET to discuss results and provide operational updates. Investors should monitor the company's investor relations site for the news release and presentation materials.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Becton, Dickinson and Company's stock, expecting it to rise in value.
Financial Health
Becton, Dickinson and Company is showing strong revenue and profits, with solid cash generation capabilities.
Dividend
Becton, Dickinson and Company's dividend yield of 2.42% offers a reasonable return for dividend-seeking investors. If you invested $1000 you would be paid $41.70 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring BDX
Healthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: October 14, 2025
Explore BasketPharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: October 12, 2025
Explore BasketHealthcare Innovation: MedTech Giants Portfolio 2025
Growing demand for advanced healthcare in Africa highlights the global companies at the forefront of medical technology innovation. This theme offers exposure to US and EU-listed industry leaders in robotic surgery, diagnostic imaging, and other medical devices.
Published: September 22, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring Revenue Base
BDX earns steady income from disposables and consumables which can smooth earnings, though results can still vary with hospital budgets and competition.
Global Healthcare Exposure
Sales span hospitals, labs and research centres worldwide, offering diversification but exposing the company to currency and regulatory risks.
Innovation & M&A
R&D and targeted acquisitions help expand the product pipeline and market share, though integration and regulatory hurdles can affect outcomes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
